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Abstract
Background: A major concern in malaria vaccine development is genetic polymorphisms typically observed
among Plasmodium isolates in different geographical areas across the world. Highly polymorphic regions have
been observed in Plasmodium falciparum and Plasmodium vivax antigenic surface proteins such as
Circumsporozoite protein (CSP), Duffy-binding protein (DBP), Merozoite surface protein-1 (MSP-1), Apical membrane
antigen-1 (AMA-1) and Thrombospondin related anonymous protein (TRAP).
Methods: Genetic variability was assessed in important polymorphic regions of various vaccine candidate antigens
in P. vivax among 106 isolates from the Amazon Region of Loreto, Peru. In addition, genetic diversity determined
in Peruvian isolates was compared to population studies from various geographical locations worldwide.
Results: The structured diversity found in P. vivax populations did not show a geographic pattern and haplotypes
from all gene candidates were distributed worldwide. In addition, evidence of balancing selection was found in
polymorphic regions of the trap, dbp and ama-1 genes.
Conclusions: It is important to have a good representation of the haplotypes circulating worldwide when
implementing a vaccine, regardless of the geographic region of deployment since selective pressure plays an
important role in structuring antigen diversity.
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Background
Malaria is one of the major global public health pro-
blems that affect most tropical regions of the world.
Even though Plasmodium falciparum is the most viru-
lent, it is estimated that Plasmodium vivax produces
around 80 to 300 million clinical cases per year [1].
Furthermore, there have been several reports of severe
P. vivax malaria cases in the last few years [2-4]. In
2008, 560,221 malaria cases were reported in the Ameri-
cas [5]; 74.2% of them caused by P. vivax and 25.7% by
P. falciparum [1]. About 90% of these malaria cases ori-
ginated in the Amazon basin shared by Bolivia, Brazil,
Colombia, Ecuador, French Guiana, Guyana, Venezuela,
Suriname and Peru [5], whereas the other 10% was con-
tributed by non-Amazon regions.
Developing a vaccine for P. vivax represents a major
challenge especially considering the lack of in vitro cul-
tures. Thus, current efforts focus on orthologs of P. fal-
ciparum. Over the past four decades, experiments
performed in animals and human subjects have led to
the development of several Plasmodium vaccine candi-
dates. Antigenic surface proteins such as the Circum-
sporozoite protein (CSP), Thrombospondin related
anonymous protein (TRAP), Duffy-binding protein
(DBP), Merozoite surface protein-1 (MSP-1) and Apical
membrane antigen-1 (AMA-1) are currently being eval-
uated as vaccine candidates in clinical trials [1,6-8]. The
CSP is one of the most extensively studied antigens and
it is involved in the motility and invasion of the sporo-
zoite during its entrance in the hepatocyte [9]. PvCSP
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amino and carboxyl sequences containing highly con-
served protein stretches (Regions I and II-plus) [10].
This protein displays two major types of nonapeptide
repeats: type I (VK210), which contains repeats of
GDRA(A/D)GQPA or related sequences and type II
(VK247), which is composed of ANGAGNQPG repeats
[11,12]. A third type of variant, called P. vivax-like has
repeat units of APGANQ(E/G)GAA, identical to that
described for Plasmodium simiovale [13,14]. Currently,
the P. falciparum RTS, S vaccine, which is based on
CSP have showed to protect semi-immune adults [15]
and children from P. falciparum natural infection in
endemic areas [16-18]; this vaccine is being tested in
Phase III clinical trials [8,19].
Another sporozoite surface protein that stands out as
ag o o dv a c c i n ec a n d i d a t ei sT R A P ,w h i c hi sa9 0k D a
protein with six distinct regions. TRAP is essential for
sporozoite gliding and hepatocyte invasion [20,21].
Genetic analysis of PvT R A Pr e v e a l st h a tm o s to ft h e
polymorphisms occur in Region II (von Willebrand fac-
tor A-domain) and III [22]. The potential role of TRAP
as a malaria vaccine candidate has been tested in mice
and monkeys, inducing high levels of specific antibodies
[23]. Furthermore, a synthetic peptide-derived from a
conserved region of the TRAP protein located in the N-
terminal, proved to be immunogenic and provided par-
tial protection in Aotus monkeys [1,24].
On the other hand, the asexual P. vivax parasite anti-
gens DBP, MSP-1 and AMA-1 have also received atten-
tion for their role in the invasion process and/or their
generation of antibody response. DBP interacts with the
Duffy blood group antigen of reticulocytes, MSP-1 is
expressed abundantly on the merozoite surface and
AMA-1 plays a role in apical reorientation of merozoites
following initial attachment during invasion [1]. Region
II of DBP (DBPII) functions as a ligand domain and con-
sists of 330 aa with 12 cysteines and numerous aromatic
residues. Studies have identified the central region of
the DBPII domain between cysteines 4 and 8, as the seg-
ment containing the conserved contact residues Tyr 94,
Asn 95, Lys 96, Arg 103 and Ile 175 required for recog-
nition of DARC (Duffy Antigen/Receptor for Chemo-
kine) on human erythrocytes [25-28].
MSP-1 is part of a complex of proteins that is pro-
cessed into smaller fragments by serine proteases during
invasion of red blood cells [29]. It has been suggested
that fragments PvMSP-114 and PvMSP-120 could be
included in a P. vivax multi-antigen vaccine since they
contain high affinity reticulocyte binding (HARB) cluster
regions and confer protection in monkeys [30-32].
AMA-1 has also been evaluated for inclusion in a multi-
sub-unit vaccine for both P. falciparum and P. vivax
[33,34]. The complete AMA-1 protein contains three
domains, from which a higher rate of mutations and
level of diversifying selection has been shown in domain
I [35,36]. Indeed, AMA-1 is highly immunogenic, pro-
tecting against Plasmodium chabaudi infection in mice
[37] and displaying significant antibody and T cell
responses in endemic human populations [38-40].
Investigation of the sequence variation among malaria
antigenic regions is necessary for the development of an
effective malaria vaccine that includes haplotypes from
different regions, considering that Plasmodium is highly
diverse and these regions are under strong immunologi-
cal pressure. In this study, important regions in PvCSP,
PvTRAP, PvDBP, PvMSP-1 and PvAMA-1 were geno-
typed using P. vivax Peruvian isolates collected during
years 2006-2007. In addition, since natural selection
plays a role in structuring diversity of these highly poly-
morphic antigens, the worldwide distribution of the
main variants was determined by comparing the Peru-
vian samples with sequences previously reported from
South America, Asia and Oceania.
Methods
Study area and sample collection
Blood samples from patients were collected during years
2006-2007 from endemic areas in the Peruvian Amazon
region of Loreto Department using human use approved
protocols (NMRCD.2005.0005). In Peru, P. vivax corre-
sponds to more than 80% of the malaria cases and the
majority of them are found in the Amazonic Depart-
ment of Loreto [41]. Fifty-seven samples were obtained
from Padrecocha, in Punchana district, a village situated
five km from Iquitos (Loreto’s capital) and forty-nine
samples were collected from a village located in the San
Juan district just south of Iquitos. All samples were con-
firmed to be positive for P. vivax by microscopic analy-
sis on Giemsa-stained blood smears.
PCR and DNA sequencing
DNA was purified from 200 μLo fw h o l eb l o o du s i n g
the QIAamp DNA Blood mini kit (QIAGEN, Valencia,
CA). PCR amplification was performed in a 50 μL reac-
tion mixture containing 0.2 μM each of forward and
reverse primers, 200 μMe a c hd N T P ,0 . 6u n i t so fD N A
polymerase recombinant (Invitrogen, Carlsbad, CA), 3
μL of 10× PCR buffer, 1.5 mM of MgCl2 and 5 μLo f
DNA extracted from blood. To assess antigenic variabil-
ity of PvCSP, the Central Repetitive Region, Region I
and Region II were amplified. The PCR conditions were:
5m i na t9 4 ° C ;1m i na t9 4 ° C ,1m i na t5 8 ° C ,2m i na t
72°C for 35 cycles; and a final extension of 72°C for 2
min, using the primers VSC-OF (5’ATGTA-
GATCTGTCCAAGGCCATAAA3’)a n dV S C - O R( 5 ’
TAATTGAATAATGCTAGGACTAACAATATG 3’)
[42]. The amplification of the highly polymorphic
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the primers Pvsspf: 5’ GTCGATTTATACCTCC-
TAGTTGACGG 3’ and Pvsspr: 5’ CAGCTTGAACGTC-
GACCTCCGC 3’ with the following conditions: 5 min
at 94°C; 1 min at 94°C, 1 min at 50°C, 2 min at 72°C for
35 cycles; and a final extension of 72°C for 2 min. The
amplification of the central region of the PvDBPII
domain was done using primers Liz-1 (5’ TGGGGAG-
GAAAAAGATG 3’)a n dL i z - 2( 5 ’ AACGGAA-
CAAACGCATAAC 3’) [43]. The PCR conditions used
were as follows: 4 min at 94°C; 1 min at 94°C, 2 min at
58°C, 2 min at 72°C for 35 cycles; and a final extension
of 72°C for 3 min. PvMSP-1 primers described by Espi-
nosa et al. (HARB1_f: 5’ GGCAACAACGATGACGAC
3’,H A R B 1 _ r :5 ’ CTTCTCAAGTCGAGCAG 3’,
HARB2_f: 5’ TCACTGTAAAGAAATTGCAG 3’ and
HARB2_r: 5’ ATACATGTGTGCTCGGAG 3’)w e r e
used for amplifying the two HARB containing regions:
PvMSP-120 and PvMSP-114 kDa [31] with the following
conditions: 5 min at 94°C; 1 min at 94°C, 1 min at 50°C,
1 min at 72°C for 35 cycles; and a final extension of 72°
C for 5 min for the first region and 5 min at 94°C; 1
min at 94°C, 1 min at 45°C, 1 min at 72°C for 35 cycles;
and a final extension of 72°C for 5 min for the second
region. Finally, a nested PCR was used to amplify
domain I of PvAMA-1 as described by Cheng and Saul
[44]. PCR products were purified using the QIAquick
PCR purifications kit (QIAGEN, Valencia, CA, USA)
and sequenced using BigDye
® Terminator v3.1 sequen-
cing kit (Applied Biosystems, Foster City, CA, USA),
with the primers previously mentioned and an ABI 3100
automated sequencer.
Sequence determination and data analysis
Sequences were analysed using the Sequencher™ soft-
ware version 4.7 (Gene Codes Corporation, Ann Harbor,
MI, USA) and sequence alignments were performed
using the MEGA software version 4.1 [45]. Comparison
with previously deposited P. vivax sequences in the
GenBank was performed using BLAST search. The
number of haplotypes (h), haplotype diversity (hd) and
nucleotide diversity (Pi) values were obtained using the
DnaSP version 5.0 [46]. The effect of natural selection
was also evaluated by estimating the difference of non-
synonymous and synonymous substitutions (Dn-Ds)
using the Nei and Gojobori’s method with the Jukes and
Cantor correction. The null hypothesis of neutrality was
rejected if Dn:Ds ≠ 1. Positive values for Dn-Ds indi-
cated positive selection while negative values indicated
negative selection [47]. Standard error was calculated
using bootstrap with 1,000 replications and rates of Ds
and Dn were compared by the Z-test of selection using
Mega version 4.1 [45]. To test whether the haplotypes
clustered according to their geographic origin, the
model-based clustering algorithm implemented in the
Structure 2.1 software was used [48]. This software uses
a Bayesian clustering approach to assign isolates to K
populations characterized by a set of allele frequencies
at each locus. The number of such populations may be
either previously known or not. The program was run
five times at different K values (from 2 to 10) with a
burn-in period of 10,000 iterations followed by 50,000
iterations. The admixture model was used in all ana-
lyses, which allows for the presence of individuals with
ancestry in two or more of the K populations. However,
clustering algorithms incorporate stochastic simulation
as part of the inference and, as a consequence, indepen-
dent analyses of the same data may result in several dis-
tinct outcomes, even though the same initial conditions
were used. To facilitate the interpretation of population-
genetic clustering results, the computer program
CLUMPP (Cluster Matching and Permutation Program)
was used. CLUMPP strips away the ‘label switching’ het-
erogeneity so that the ‘genuine multimodality’ can be
detected and quantified [49]. In addition, distruct 1.1
was used to graphically display the clustering results
[50]. The genetic difference between clusters was mea-
sured by the fixation index (Fst) calculated from the
haplotype frequencies (Hst) and pair-wise DNA
sequence diversity (Kst*) using DnaSP version 5.0 [46].
The nearest-neighbour statistic (Snn) was also calculated
between geographic populations. Snn is a measure of
how often the “nearest neighbours” of sequences are
from the same locality in geographic space. This statistic
is applicable when genetic data are collected on indivi-
duals sampled from two or more localities. Snn is
expected to be near one when the populations at the
two localities are highly differentiated and near one-half
when the populations at the two localities are part of
the same pan-mictic population [51].
Results
PvCSP
A 1,100 bp PCR product corresponding to Pvcsp was
amplified from 106 P. vivax samples from Peru. In addi-
tion, 326 complete CSP sequences from Brazil, Colom-
bia, India, Iran and Korea were also included in the
amino acid alignment. Sequences from Thailand, China
and PNG were used to determine the percentage of
strains circulating of each PvC S Pt y p e( T a b l e1 ) ;h o w -
ever, they were not considered in the haplotype analysis
since the sequences were not complete. Most of the
strains circulating worldwide belonged to the VK210
type and in most population sets analysed (except
Colombia and Thailand) a greater percentage of VK210
haplotypes was found. The amino acid alignment of the
sequences used in this study showed 97 different VK210
haplotypes and 28 VK247 haplotypes circulating
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American and Asian countries, except for one VK247
Peruvian haplotype, which was also found in Iran [52].
Thirty-seven VK210 and 19 VK247 haplotypes were
identified in South America; while in Asia, 51 and 10
haplotypes were observed from each type.
In Peru, 23 different VK210 subtypes and three different
VK247 subtypes were found (Figure 1). PvCSP displayed a
different pattern of a nine amino acid oligopeptide repeti-
tions depending on the subtype. The VK210 subtypes con-
tained the repeat region G(D/N)RA(A/D/G/V)G(Q/H)PA
either 16, 17, 18 or 19 times, while VK247 subtypes
Table 1 Population data set for PvCSP (* Submission year, ? partial sequences)
Region Country Year of
collection
GenBank Accession Number N % VK210-
VK247
H
South
America
Brazil 2000 DQ978648-DQ978690 43 100 -0 16
Colombia 2009 GU339059-GU339086 28 11.2-88.8 20
South
Asia
India 2008* FJ491063-FJ491141 79 100 -0 44
South
East Asia
Thailand 2009* HQ011279-HQ011323 45 40-60 ?
East Asia Korea 2006* DQ859734-DQ859772 39 100-0 7
China 2008* FJ601724-FJ601761 38 100-0 ?
Western
Asia
Iran 2000-2003 AY367278-AY367303, AY632256-AY632287, AY443700-AY4443725, AY632288-AY632318,
AY632243-AY632251, AY632319-AY632330, AY443726
137 76.5-23.5 25
Oceania PNG 1999, 2001,
2003
EU031819-EU031836 17 70.6-29.4 ?
A) 
 
PER01  NKLKQP 1 1 1 2 1 1 1 1 2 2 1 2 1 2 1 2 2 2 2 GNGAGGQAAGGNAGGQGQNNEGANAPNEKSVKEYLDKVRATVGTEWTPCSVTCGVGVRVRRRVNAANKKP
PER02  ...... 1 1 1 1 1 1 1 1 1 3 1 1 1 1 1 2 2 2   ......................................................................
PER03  ..V... 1 1 1 1 1 3 1 1 1 1 1 1 1 1 1 1 1     ......................................................................
PER04  ...... 1 1 1 2 1 1 1 1 2 2 1 2 1 2 1 6 2 2 2 ......................................................................
PER05  ..V... 1 1 1 2 1 1 1 1 2 2 1 2 1 2 1 2 2 2 2 ......................................................................
PER06  ...... 1 1 1 1 2 1 1 1 1 2 1 2 1 2 1 2 2 2   .DR.A.................................................................
PER07  ...... 1 1 1 1 1 3 1 1 1 1 1 1 1 1 1 1 1     ......................................................................
PER08  ..V... 1 1 2 1 1 1 1 1 1 3 1 1 1 1 1 2 2 2   ......................................................................
PER09  ...... 1 1 1 2 1 1 1 1 2 2 1 2 1 2 2 2 2 2   ......................................................................
PER10  ...... 1 1 1 1 1 1 1 1 5 2 1 1 1 1 2 2 2 2   ......................................................................
PER11  ...... 1 1 1 1 1 1 1 1 1 2 1 2 1 2 1 2 2 2 2 ......................................................................
PER12  ...... 1 1 1 1 3 1 1 1 1 1 1 1 1 1 1 1       ......................................................................
PER13  ...... 1 1 1 2 1 1 1 1 1 4 1 2 1 2 1 2 2 2 2 ......................................................................
PER14  ...... 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 2 2   .DR.A.................................................................
PER15  ...... 1 1 1 1 2 1 1 1 1 2 2 1 2 1 2 1 2 2 2 .DR.A.................................................................
PER16  ...... 1 1 2 1 1 2 1 1 1 1 2 2 1 2 1 2 2 2   ......................................................................
PER17  ...... 1 1 1 2 1 1 1 1 2 1 2 1 2 1 2 2 2 2 2 ......................................................................
PER18  ...... 1 1 1 1 1 1 1 1 3 1 1 1 1 1 2 2 2 2   ......................................................................
PER19  ...... 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 2 2     ......................................................................
PER20  ...... 1 1 1 2 1 1 1 1 2 1 2 1 2 1 2 2 2     .DR.A.................................................................
PER21  ...... 1 1 1 1 2 1 1 1 2 2 1 2 1 2 1 2 2 2   .DR.A.................................................................
PER22  ...... 1 1 1 1 1 2 1 1 1 1 2 1 2 1 2 1 2 2 2 .DR.A.................................................................
PER23  ...... 1 1 1 2 1 1 1 1 2 2 1 1 1 2 2 2 2 2   ......................................................................
           
1 GDRADGQPA         
2 GDRAAGQPA 
3 GNRADGQPA 
4 GDRAGGQPA 
5 GDRAAGHPA 
6 GDRAVGQPA 
 
 
B) 
 
PER24 NKLKQPEDGAGDQPG 11111121113131111  GDAGAGQGQNNEGANAPNEKSVEYLDKVRTTVGTEWTPCSVTCGVGVRVRRRVYSANKKP 
PER25 ............... 311111121113131111 ............................................................ 
PER26 ............... 11111121111131111  ............................................................ 
 
1 ANGAGNQPG 
2 ANGADDQPG 
3 ANGAGDQPG 
Figure 1 Amino acid alignment of the 27 PvCSP haplotypes bearing a) the VK210 repeat type and b) the VK247 repeat type in
Peruvian samples.
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or 18 times. Region I of PvCSP showed a polymorphism in
position 3 (L/V), whereas the 18 amino acid long linear
peptide EWTPCSVTCGVGVRVRRR, located on Region II
[53,54], was highly conserved. PvCSP analysis of Peruvian
isolates also revealed high variability of VK210 and VK247
haplotypes compared to other populations from South
America [55,56]. Region II-plus, which contains dominant
B-cell epitopes [57,1] and block hepatocyte invasion by
sporozoites [58], was highly conserved in Peruvian isolates,
with the same amino acid sequence as the Sal I strain.
PvTRAP
A total of 104 sequences of regions II and III of Pvtrap
were obtained from the Peruvian isolates. In addition,
63 Thailand sequences from GenBank were included in
the amino acid alignment. The N-terminal region (209-
256aa), which has been proved to be immunogenic and
to provide partial protection in Aotus monkeys [24] was
highly conserved with only three amino acid substitu-
tions in positions 216 (R/K), 219 (H/Q) and 229 (G/K).
In general, more diversity was found in Thailand (h =
34, π = 0.007 ± 0.00029 and Hd = 0.961 ± 0.01) (Table
2) compared to Peru (h = 7, π = 0.00235 ± 0.00012 and
Hd = 0.641 ± 0.026) and according to the Dn-Ds test,
regions II and III of Pvtrap were under positive selection
(Table 3).
PvDBP
A 1,150 bp DNA fragment of Pvdbp was amplified from
all 106 Peruvian isolates and 601 P. vivax sequences
from Brazil, Colombia, India, Sri Lanka, Thailand,
Korea, Iran and Papua New Guinea were also included
in the analysis. The alignment of 510 bp from region II
of dbp showed 150 different haplotypes, from which 39
were found in South America, 42 in Asia, 56 in Oceania
and 13 were found in South America and Asia. In the
Peruvian isolates 26 different haplotypes were found
with genetic diversity values of π = 0.008 ± 0.00048 and
Hd = 0.903 ± 0.014. In general, the average genetic and
haplotype diversity in South America and Asia was very
similar (Table 2). On the other hand, the analysis of
DNA sequence polymorphisms showed a significant dif-
ference between synonymous and non-synonymous sub-
stitutions, indicating balancing selection in dbpII (Table
3). In addition, several substitutions in the positions
underlined were found in DBPII regions corresponding
to peptides H1: FHRDITFRKLYLKRKL, H3: DEKA
QQRRKQWWNESK an 1653: RDYVSELPTEVQKLKE
KC, previously reported as immunogenic [27,59].
PvMSP-1
According to the amino acid alignment of PvMSP-120
and PvMSP-114, a total of 28 haplotypes were found
worldwide, 11 in South America, 14 in Asia and three
in both continents. When comparing genetic diversity
between populations, Peru (π = 0.00286 ± 0.00029, Hd
= 0.665 ± 0.041) and Brazil (π = 0.00293 ± 0.00061, Hd
= 0.75 ± 0.139) showed the highest levels of nucleotide
and haplotype diversity, while in Korea, Thailand and
Turkey these HARBs were highly conserved. In general,
values of genetic diversity for Pvmsp-1 were low when
compared with the other genes and no clear signature
of selection was found according to the Dn-Ds test
(Table 3).
PvAMA-1
The polymorphic region of Pvama-1 (Domain I of pro-
tein) was amplified and sequenced from 98 of the 106
Peruvian isolates. A total of 774 Pvama-1 partial
sequences were used in the analysis, including samples
from Brazil, Venezuela, India, Sri Lanka, China, Korea,
Myanmar, Philippines, Thailand, Papua New Guinea and
Solomon Islands. A total of 168 haplotypes were identi-
fied; 135 were exclusively found in Asia, nine in Oceania
and 12 in South America. In addition, seven haplotypes
were shared in America and Asia and five in Asia and
Oceania. According to the analysis of polymorphisms,
the dN-dS test indicated balancing selection in this
domain (Table 3) with several haplotypes in low fre-
quency. In addition, values of nucleotide diversity were
very similar between geographic regions and populations
(Table 2).
Population genetic analysis
When analysing Plasmodium isolates, samples are
usually grouped by geographic location; nevertheless,
this approach assumes that geographic barriers or dis-
tance are the underlying factors that limit gene flow.
It also assumes that genetic exchange within each
population geographically defined is random. To bet-
ter estimate the distribution of haplotypes of different
P. vivax vaccine candidate antigens, a Bayesian clus-
tering algorithm [48] was used to sub-group samples
according to related SNPs haplotypes. The Structure
model assumes that loci are independent within popu-
lations; however, this assumption is likely to be vio-
lated for sequence data, or data from non-
recombining regions. It is a matter of debate whether
it is valid to group sequences containing potentially
l i n k e dp o l y m o r p h i s m si nas i n g l eg e n eu n d e rb a l a n -
cing selection [60]. The main cost of the dependence
within regions will be that Structure underestimates
the uncertainty in the assignment of particular indivi-
duals. However, if there is enough independence
across regions than LD within regions, then Structure
may actually perform reasonably well [48]. Moreover,
our main goal is not to describe the demographic
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representation of the vaccine candidate’sh a p l o t y p e
distribution. Genetic differentiation between clusters
was calculated using Fst from haplotype-frequencies
and pairwise DNA sequence diversity. The haplotype
frequency-based statistics are more sensitive for small
sample sizes, while the sequence-based statistic is a
more sensitive method for detecting population struc-
ture in highly polymorphic loci [61,62].
The results obtained with PvTRAP, PvDBP and
PvAMA-1 showed three different clusters. Significant
differentiation was observed in haplotype and pair-wise
comparisons between all clusters according to the Fst
values (Table 4), except for Pvmsp-1,f r o mw h i c has i g -
nificant number of clusters it was not possible to iden-
tify. Although admixed haplotypes were observed in
Pvdbp and Pvama-1, the estimate of K = 3 best
explained the distribution of haplotypes from all
Table 2 Estimates of Plasmodium vivax genetic diversity using GenBank sequences
Antigen Region Country N GenBank Accession Number H π (s.d.) Hd (s.d.)
TRAP South
East Asia
Thailand 63 AF312559-AF312661 34 0.00707 (0.00029) 0.961 (0.01)
DBPII South
America
Brazil 126 DQ156520, EU812839-EU812960, EU870443-EU870445 24 0.00919 (0.00042) 0.883 (0.018)
Colombia 17 DQ156513, U50575-U50590 12 0.00812 (0.00081) 0.956 (0.033)
South
Asia
India 101 DQ156516, FJ491142-FJ491241 28 0.01011 (0.00063) 0.86 (0.028)
Sri Lanka 100 GU143914-GU144013 14 0.00864 (0.00063) 0.738 (0.039)
South
East Asia
Thailand 30 EF219451, EF368159-EF368178, EF379127-EF379135 19 0.01628 (0.00354) 0.972 (0.018)
East Asia Korea 16 EU395592, DQ156515, DQ156522-DQ156523, AF215737-AF215738,
AF220657, AF220659-AF220667
11 0.00817 (0.00149) 0.933 (0.048)
Western
Asia
Iran 11 EU860428-EU860438 8 0.01047 (0.00205) 0.945 (0.054)
Oceania Papua
New
Guinea
200 AF291096, AF289653, AF469515-AF469602, DQ156512-DQ156523,
AY970837-AY970925
59 0.01166 (0.00041) 0.888 (0.015)
MSP-1 South
America
Brazil 8 AF435622-AF435625, AF435627, AF435629-AF435631 4 0.00293 (0.00061) 0.75 (0.139)
South
East Asia
India 28 EU430452-EU430479 6 0.0172 (0.00049) 0.489 (0.112)
Thailand 170 GQ890872-GQ891041 2 0.00013 (0.00005) 0.068 (0.026)
Singapore 50 GU971656-GU971705 10 0.0019 (0.00032) 0.407 (0.09)
Western
Asia
Turkey 30 AB564559-AB564588 2 0.00073 (0.00034) 0.186 (0.088)
East Asia Korea 8 HQ171941-HQ171934 1 0 0
AMA-1 South
America
Brazil 65 EF031154-EF031216, EF031183, EF031184 12 0.01358 (0.00056) 0.866 (0.02)
Venezuela 73 EU346015-EU346087 12 0.01368 (0.00053) 0.847 (0.019)
South
Asia
India 189 EU282774-EU282822, FJ490963-FJ491062, EF025187-EF025197, GU086369-
GU086382, AF171250-AF171254, AF171256, AF171258-AF171260,
AF171262-AF171267
68 0.01427 (0.00036) 0.945 (0.008)
Sri Lanka 23 EF218679-EF218701 8 0.00722 (0.00148) 0.83 (0.054)
East Asia China 7 AF171243-AF171249 6 0.01211 (0.00193) 0.893 (0.111)
Korea 6 AF357212, AF357213, GU476488, EU395599, AF402593, AF402594 4 0.00812 (0.00328) 0.9 (0.161)
South
East Asia
Myanmar 39 FJ157247-FJ157285 36 0.01833 (0.00092) 0.996 (0.007)
Philippines 110 AF171273-AF171382 20 0.01474 (0.0005) 0.802 (0.029)
Thailand 235 FJ784891-FJ85121, AF17453-AF171456 44 0.01488 (0.00039) 0.899 (0.011)
Oceania PNG 22 AF171421-AF171426, AF171428-AF171443 13 0.01379 (0.00163) 0.913 (0.045)
Solomon
Islands
5 AF171444, AF171445, AF171447, AF171449, AF171450 5 0.01855 (0.00318) 1 (0.126)
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Page 6 of 11geographic populations; besides, the defined sub-groups
were not geographically or even regionally restricted
(Figure 2). Snn values between the different geographic
populations were also calculated for each of the anti-
gens. We observed that for most of the comparisons in
DBP, AMA-1 (Table 5) and TRAP (Snn = 0.86803*),
Snn values were near one, which indicates that the
localities are highly differentiated. However, close geo-
graphic populations such as Sri Lanka and India in
South Asia and Peru and Brazil in South America
showed almost not genetic differentiation (Snn = 0.58, p
< 0.01 and Snn = 0.65, p < 0.01). Thus, relative low Snn
values were found between Brazil, India and Sri Lanka,
s i n c et h e r ea r es h a r e dh a p l o types circulating in South
America and South Asia. Moreover, previous work also
indicated low genetic differentiation using Fst analysis
between dbpII sequences from Brazil and Iran, India or
Sri Lanka [63]. On the other hand, at least seven of the
pairwise comparisons made using MSP-1 resulted in
non-significant values.
Discussion
When designing an efficient anti-malarial vaccine,
worldwide information of the circulating antigenic var-
iants is necessary for the formulation of a polyvalent
vaccine, which would be effective in different regions.
Because of the complex parasite life cycle and the co-
existence of P. falciparum and P. vivax infections in
most endemic areas, it is accepted that a multi-antigen
and multi-species vaccine should be developed for most
endemic regions [1]. In P. falciparum, the majority of
haplotypes upon which current vaccines are based have
been found to be present at extremely low frequencies
in the global parasite population, except for lsa-1 and
msp-1 haplotypes [62]. Since immune selection might be
playing a role in structuring the diversity of highly poly-
morphic antigens, population genetic studies in endemic
regions are essential for the next generation of vaccines.
In this study, the information obtained from the Peru-
vian isolates contribute to get a better understanding of
the haplotypes circulating in the Amazon basin and to
compare these results with other previously reported
from different parts of the world.
For the analysis of Peruvian isolates, samples form
Padreococha and San Juan were considered as a single
geographic population since these areas are relatively
closed and they present similar haplotype distribution
in all antigens with little or none genetic differentia-
tion between them. In general, data from a two-year
period (2006-2007) in Peru revealed high nucleotide
and haplotype diversity compared to other geographic
populations included in the final analysis. These results
suggest that the extent of allelic diversity in this region
is determined by complex demographic processes that
include heterogeneity of transmission intensities in
time and space, as well as the number of recurrent
infections that are common in the region, allowing for
a high turnover of parasite genotypes [41]. The pre-
sence of asymptomatic cases [64] participating in the
infection process might also be contributing to the
persistence of genetic variation since they are a “reser-
voir” of untreated patients. In addition, we need to
take in consideration possible P. vivax multi clonal
infections that might be diff i c u l tt oo b s e r v eb yd i r e c t
sequencing. This limitation could potentially affect the
overall estimates of genetic diversity and population
structure; however, for the goal of this study, the data
collected is useful to obtain a broad picture of how
these vaccine candidate haplotypes are worldwide dis-
tributed. If a fine scale study is considered in which
the goal is to understand the population structure of
Plasmodium i nas p e c i f i cg e o g r a p h i ca r e at h e n ,
unlinked microsatellite loci should be used to get a
better idea of the parasite’s population history.
Table 3 Summary of genetic data of the Plasmodium vivax vaccine antigens analysed including Sal I sequence.
Antigen Expression Domain Sites N H π (s.d.) Hd (s.d.) dN-dS (s.d.) Ztest (dN ≠ dS)
Dbp Merozoite Region II 510 707 150 0.01103 (0.00025) 0.9319 (0.0053) 0.009 (0.003) P < 0.05
Msp-1 Merozoite MSP114 and MSP120 512 400* 28 0.00129 (0.00014) 0.358 (0.031) 0.001 (0.001) n.s.
Ama-1 Merozoite Domain I 345 872 168 0.01653 (0.00016) 0.9691 (0.0017) 0.012 (0.004) P < 0.05
Trap Sporozoite Regions 837 168 38 0.0059 (0.00029) 0.854 (0.018) 0.007 (0.002) P < 0.05
*Belem sequence included
Table 4 Estimation of genetic differentiation between
clusters of populations obtained by Structure.
A)
Antigen 1 vs 2 1 vs 3 2 vs 3
DBP 0.13742* 0.18583* 0.11845*
AMA-1 0.09891* 0.06873* 0.06239*
TRAP 0.2478* 0.3393* 0.12982*
B)
Antigen 1 vs 2 1 vs 3 2 vs 3
DBP 0.34601* 0.4555* 0.41168*
AMA-1 0.50583* 0.31637* 0.177725*
TRAP 0.71399* 0.60509* 0.64183*
FST calculated from A) haplotype frequency and B) sequence diversity with *P
< 0.001
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Page 7 of 11When considering worldwide data, genes encoding
non-merozoite antigens in P. falciparum showed varia-
tion in diversity [62]. In P. vivax, the same pattern was
observed using CSP and TRAP. Although, limited popu-
lation samples were available for TRAP sequences. On
the other hand, the genes encoding merozoite antigens
in P. falciparum and P. vivax showed different patterns.
P. falciparum genes encoding AMA-1, EBA-175 and
MSP-1, MSP-3 and MSP-4 showed similar levels of
diversity among countries and regions [62]. In P. vivax,
genes dbpII and ama-1 also showed this trend; however,
msp-1 exhibited very low but different polymorphism
and haplotype diversity values among regions and coun-
tries. These results support the hypothesis that main-
taining the structural conformation of the HARBs
regions (MSP-120 and MSP-114) is important for recog-
nition and binding of reticulocytes [31]. The limited var-
iation of amino acid substitutions in these fragments
makes them strong candidates to be tested in immuno-
logical studies. Also, TRAP sequences showed low levels
of nucleotide and haplotype diversity with a highly con-
served region between positions 209 to 256, previously
reported to be immunogenic.
Contrary to P. falciparum, a largely structured diver-
sity in all P. vivax populations was not found on the
basis of geography. The clusters determined by Struc-
ture were found in most countries except in those with
small number of samples, suggesting that haplotypes
corresponding to those clusters were underrepresented.
Moreover, a high level of admixture in all countries was
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Figure 2 Global population structure of the genes encoding P.vivax vaccine antigens based on Bayesian cluster analysis.E a c h
haplotype is represented by an imaginary bar, which is partitioned into K coloured segments that represent the membership fraction of each
haplotype in K clusters (K = 3, represented by the three different colours blue, yellow and orange). Samples are grouped in boxes according to
their geographic origin.
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Page 8 of 11observed, which could be explained by natural and high
fluctuations over time, as a result of frequency-depen-
dent selection or the discrepancy due to the sampling
used [62], since the worldwide sequences obtained from
GenBank came from different time points and locations.
On the other hand, the lack of geographic clustering
could be explained by balancing selection acting on the
genes studied and as a result high worldwide antigen
diversity was observed not only in Asia but also in
South America.
Conclusion
In conclusion, it would be ideal to have a good repre-
sentation of the haplotypes circulating worldwide when
implementing a vaccine regardless of the geographic
region of deployment. Considering that selective pres-
sure plays an important role in structuring the diversity
of antigens, it cannot be assumed that a single strain
could accurately represent the haplotypes circulating
worldwide and as a consequence be effective in all ende-
mic regions. In addition, Plasmodium population
definition should be revised since parasite sub-groups
are not necessarily geographically restricted and treat-
ment or vaccination in a region cannot be considered as
if it was isolated but a dynamic map needs to be
acknowledged. Thus, important epidemiological units
should be established according to the parasite’sg e n e
flow, which would lead to a more effective malaria con-
trol strategy.
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